Document Detail

Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
MedLine Citation:
PMID:  22995880     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The goal of this analysis was to determine the association between intraprocedural complications and clinical outcomes among patients with high-risk non-ST-segment elevation acute coronary syndrome (NSTEACS) undergoing percutaneous coronary intervention (PCI).
BACKGROUND: Among patients undergoing PCI for NSTEACS, the relationship between intraprocedural complications and clinical outcomes, independent of epicardial and myocardial perfusion, has not been well characterized.
METHODS: The EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) trial enrolled 9,406 patients with high-risk NSTEACS undergoing an early invasive strategy. Of these, 1,452 underwent angiographic assessment in an independent core laboratory and did not have a myocardial infarction (MI) between enrollment and angiography. We assessed the relationship between abrupt closure, loss of side branch(es), distal embolization, and no-reflow phenomenon and 30-day clinical outcomes in these patients.
RESULTS: Of the patients, 166 (11.4%) experienced an intraprocedural complication. Baseline clinical characteristics were similar between patients who did and did not have complications. The 30-day composite of death or MI was significantly higher among patients with an intraprocedural complication (28.3% vs. 7.8%, odds ratio [OR]: 4.68, 95% confidence interval [CI]: 3.2 to 7.0, p < 0.001). Individually, both mortality (3.0% vs. 0.9%, OR: 3.60, 95% CI: 1.2 to 10.5, p = 0.019) and MI (27.1% vs. 7.4%, OR: 4.66, 95% CI: 3.1 to 7.0, p < 0.001) were significantly increased. After adjusting for differences in post-PCI epicardial and myocardial perfusion, the association with 30-day death or MI remained significant.
CONCLUSIONS: Among high-risk NSTEACS patients undergoing an invasive strategy, the incidence of intraprocedural complications is high, and the occurrence of these complications is associated with worse clinical outcomes independent of epicardial and myocardial perfusion. (Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome [EARLY ACS]; NCT00089895).
Yuri B Pride; Satishkumar Mohanavelu; Cafer Zorkun; Vijayalakshmi Kunadian; Robert P Giugliano; L Kristin Newby; Eugene Braunwald; Robert M Califf; Robert A Harrington; C Michael Gibson;
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  JACC. Cardiovascular interventions     Volume:  5     ISSN:  1876-7605     ISO Abbreviation:  JACC Cardiovasc Interv     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-21     Completed Date:  2013-02-12     Revised Date:  2014-09-05    
Medline Journal Info:
Nlm Unique ID:  101467004     Medline TA:  JACC Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  927-35     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / blood,  mortality,  physiopathology,  radiography,  therapy*
Anticoagulants / therapeutic use
Biological Markers / blood
Chi-Square Distribution
Coronary Angiography*
Coronary Circulation
Drug Therapy, Combination
Heart Diseases / etiology,  mortality,  radiography*
Kaplan-Meier Estimate
Logistic Models
Middle Aged
Myocardial Infarction / etiology,  radiography
North America
Odds Ratio
Percutaneous Coronary Intervention / adverse effects*,  mortality
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*,  metabolism
Predictive Value of Tests
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Troponin / blood
Reg. No./Substance:
0/Anticoagulants; 0/Biological Markers; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Troponin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analys...
Next Document:  Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarctio...